The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis

scientific article published on 23 May 2014

The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1008410004
P356DOI10.1245/S10434-014-3798-Z
P698PubMed publication ID24854493

P50authorGuillermo Flores-AyalaQ114522558
Alberto Gomez-PortillaQ114522559
Mecker MollerQ114522560
Guillaume PassotQ114522561
Marc PocardQ114522562
George SaltiQ114522564
Juan Torres-MeleroQ114522565
Marcello DeracoQ43800082
Dario BarattiQ43800097
Armando SardiQ57019761
Olivier GlehenQ57655409
Shigeki KusamuraQ59555769
Kiran K TuragaQ84946648
Richard BerriQ85408607
Jesus EsquivelQ88222940
Evgenia HalkiaQ88925925
Santiago González-MorenoQ89017697
Terence C ChuaQ90254454
Andrew M LowyQ90616308
Maheswari SenthilQ96341637
Joerg O PelzQ114522554
Joel M BaumgartnerQ114522556
Pedro Bretcha-BoixQ114522557
P2093author name stringMaurie Markman
Richard Trout
John Spilioitis
Martin Goodman
P2860cites workComprehensive molecular characterization of human colon and rectal cancerQ24630415
Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal originQ33777576
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trialQ34581085
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimenQ34642136
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.Q35721069
Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma.Q36571925
Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapyQ37662262
Summary of current therapeutic options for peritoneal metastases from colorectal cancerQ38017942
Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United StatesQ38116391
Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.Q43932503
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.Q46755325
Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy.Q47787166
Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: A multi‐institutional studyQ53264117
Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.Q53286355
P433issue13
P921main subjectcolorectal cancerQ188874
colorectal carcinomaQ25493920
P304page(s)4195-4201
P577publication date2014-05-23
P1433published inAnnals of Surgical OncologyQ2853069
P1476titleThe American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis
P478volume21

Reverse relations

cites work (P2860)
Q60922822A Simplified Peritoneal Sarcomatosis Score for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Q26772268Abdominal metastases from colorectal cancer: intraperitoneal therapy
Q37280394Bowel strangulation caused by massive intraperitoneal adhesion due to effective chemotherapy for multiple peritoneal metastases originating from descending colon cancer
Q47849422Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions-A systematic review.
Q64092130Colorectal Peritoneal Metastases: A Systematic Review of Current and Emerging Trends in Clinical and Translational Research
Q53102271Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort.
Q36762307Computerized System for Staging Peritoneal Surface Malignancies
Q49774282Curative versus palliative treatments for colorectal cancer with peritoneal carcinomatosis: a systematic review and meta-analysis
Q64116538Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study
Q39964992Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
Q36160064Cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinomatosis: Our initial experience and technical details
Q26768376Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection
Q41547533Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence
Q52974833Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC.
Q28077394Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Management of Peritoneal Carcinomatosis
Q92200782Impact of anesthesia management during cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for the treatment of colorectal peritoneal carcinomatosis on intra- and postoperative outcomes: A systematic review protocol
Q26849259Looking up: Recent advances in understanding and treating peritoneal carcinomatosis
Q37571642Multidisciplinary Treatment for Colorectal Peritoneal Metastases: Review of the Literature
Q26769938Multimodality treatment strategies have changed prognosis of peritoneal metastases
Q60912302Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study
Q91671852Outcome of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer
Q39442876Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer
Q40242470Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis
Q94410844Preoperative Management of Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Q90392289Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC
Q47789478Prospective Quality of Life Study for Colorectal Cancer Patients with Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Q38765792Registries on peritoneal surface malignancies throughout the world, their use and their options.
Q64064235Second and third look laparoscopy in pT4 colon cancer patients for early detection of peritoneal metastases; the COLOPEC 2 randomized multicentre trial
Q37354819Short-term outcome in patients treated with cytoreduction and HIPEC compared to conventional colon cancer surgery
Q38780368Surveillance after curative treatment for colorectal cancer
Q51000263Survival and Prognostic Factors for Metachronous Peritoneal Metastasis in Patients with Colon Cancer.
Q40507435The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score.
Q28067123Therapeutic options for peritoneal metastasis arising from colorectal cancer
Q39406537Treatment of peritoneal carcinomatosis with hyperthermic intraperitoneal chemotherapy in colorectal cancer.
Q26744031Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives
Q38816501What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures

Search more.